PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 90517616 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 116 |
MARK SECTION | |
MARK | SALIOGASE (see, http://uspto.report/TM/90517616/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | SALIOGASE |
OWNER SECTION (current) | |
NAME | Saliogen Therapeutics, Inc. |
MAILING ADDRESS | 245 First Street, 18th Floor |
CITY | Cambridge |
STATE | Massachusetts |
ZIP/POSTAL CODE | 02142 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
XXXX | |
OWNER SECTION (proposed) | |
NAME | Saliogen Therapeutics, Inc. |
MAILING ADDRESS | 245 First Street, 18th Floor |
CITY | Cambridge |
STATE | Massachusetts |
ZIP/POSTAL CODE | 02142 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Rachelle A. Dubow, Esq. |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@morganlewis.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | rachelle.dubow@morganlewis.com; michelle.raynes@morganlewis.com; jennifer.kagan@morganlewis.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Rachelle A. Dubow, Esq. |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@morganlewis.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | rachelle.dubow@morganlewis.com; michelle.raynes@morganlewis.com; jennifer.kagan@morganlewis.com |
DOCKET/REFERENCE NUMBER | 126933-0003 |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 001 |
CURRENT IDENTIFICATION | Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research |
GOODS OR SERVICES | KEEP ALL LISTED |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological, dyslipidemias musculoskeletal, oncological disorders and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 2 |
ONGOING EFFORT | product or service research or development |
ALLOWANCE MAIL DATE | 12/14/2021 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 2 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 250 |
TOTAL AMOUNT | 250 |
SIGNATURE SECTION | |
SIGNATURE | /Jeffrey Kopacz/ |
SIGNATORY'S NAME | Jeffrey Kopacz |
SIGNATORY'S POSITION | Senior Vice President-Head of Intellectual Property & Contracts |
DATE SIGNED | 12/12/2022 |
SIGNATORY'S PHONE NUMBER | 857-990-2200 |
SIGNATURE METHOD | Sent to third party for signature |
FILING INFORMATION | |
SUBMIT DATE | Mon Dec 12 17:55:12 ET 2022 |
TEAS STAMP | USPTO/ESU-XXX.XXX.XX.XXX- 20221212175512748925-9051 7616-850cccd5efbff6849c54 f5c2ca46b8fa98181c1ae9a43 e664356e9977e27285c52b-DA -55122501-202212121147479 02262 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |